TourbahALebrun-FrenayCEdanG, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler2016; 22: 1719–1731.
2.
WolfBGrierREAllenRJ, et al. Biotinidase deficiency: The enzymatic defect in late-onset multiple carboxylase deficiency. Clin Chim Acta1983; 131: 273–281.
3.
WolfBHeardGSWeissbeckerKA, et al. Biotinidase deficiency: Initial clinical features and rapid diagnosis. Ann Neurol1985; 18: 614–617.
4.
WolfB.The neurology of biotinidase deficiency. Mol Genet Metab2011; 104: 27–34.
5.
SalbertBAAstrucJWolfB.Ophthalmologic findings in biotinidase deficiency. Ophthalmologica1993; 206: 177–181.
6.
WolfB. Biotinidase deficiency: “If you have to have an inherited metabolic disease, this is the one to have.”Genet Medicine2012; 14: 565–575.
7.
HeardGSWolfBJeffersonLG, et al. Neonatal screening for biotinidase deficiency: Results of a 1-year pilot study. J Pediatr1986; 108: 40–46.
8.
WolfB.Worldwide survey of neonatal screening for biotinidase deficiency. J Inherited Metab Dis1991; 14: 923–927.
9.
WolfB.Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening. Genet Med. Epub ahead of print 22September2016. DOI: 10.1038/gim.2016.135.
BottinLPrud’honSGueyS, et al. Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood. Multiple Sclerosis Journal2015; 21: 1604–1607.
12.
RahmanSStandingSDaltonRN, et al. Late presentation of biotinidase deficiency with acute visual loss and gait disturbance. Dev Med Child Neurol1997; 39: 830–831.
13.
WolfB.Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without vision loss. Mol Genet Metabol2015; 116: 113–118.
14.
SedelFPapeixCBellangerA, et al. High doses of biotin in chronic progressive multiple sclerosis: A pilot study. Mult Scler Relat Disord2015; 4: 159–169.
15.
SedelFBernardDMockD, et al. Targeting demyelination and virtual hypoxia with high-dose biotin as treatment for progressive multiple sclerosis. Neuropharmacology2016; 110: 644–653.
